Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05975840 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 518
- Enrollment target
NCT05975840: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT05975840 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 518 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (763% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05975840, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 518 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (\>=)18 years of age.
Primary Outcome
Antibody titers were presented as geometric mean titers (GMTs).
Interventions
- BIOLOGICAL FLU Q-PAN H5N8 375_B
- BIOLOGICAL FLU Q-PAN H5N8 375_A
- BIOLOGICAL FLU Q-PAN H5N8 750_B
- BIOLOGICAL FLU Q-PAN H5N8 750_A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2023-08-03 |
| Est. Completion | 2024-09-19 |
| Phase | Phase 1 |
What the finished NCT05975840 record still lists
NCT05975840 is an interventional study that assigns participants to a tested intervention. The registered 518 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (763% higher).
The record links to 0 conditions, and to 4 interventions - of which FLU Q-PAN H5N8 375_B is the first listed.
NCT05975840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05975840 about?
NCT05975840 is a clinical study titled "Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults". The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (\>=)18 years of age.
What is the current status of trial NCT05975840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 518 participants. The study started on 2023-08-03. Estimated completion is 2024-09-19.
What interventions are being tested in trial NCT05975840?
The interventions under investigation include: FLU Q-PAN H5N8 375_B (BIOLOGICAL), FLU Q-PAN H5N8 375_A (BIOLOGICAL), FLU Q-PAN H5N8 750_B (BIOLOGICAL), FLU Q-PAN H5N8 750_A (BIOLOGICAL).
Who is sponsoring clinical trial NCT05975840?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05975840's enrollment target sits among peer trials
518 40th of 2000 higher than 1,960 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04524871 · 518 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- NCT07112196 · 518 participants · Phase 2
Visugromab in Cachexia International Trial
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI